Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Combined Epigenetic Therapy to Induce Latency II/III Antigen Expression in Latency I EBV + Lymphoma

Isabella Y Kong, Sarah E Clark, Suhong Sun, Vicenta Trujillo-Alonso, Alicia Alonso, Roberta Zappasodi, Ethel Cesarman, Lisa Giulino Roth

Blood (2024) 144 (Supplement 1): 7182.

https://doi.org/10.1182/blood-2024-201570

Published: 2024

Journal Articles

Single Cell Transcriptome of Epstein Barr Virus-Associated Burkitt Lymphoma from People Living with Human Immunodeficiency Virus

Maria Montserrat Aguilar Hernandez, Isabella Y Kong, Amy Chadburn, Lisa Giulino Roth, Ethel Cesarman

Blood (2024) 144 (Supplement 1): 6195.

https://doi.org/10.1182/blood-2024-212098

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 462.

https://doi.org/10.1182/blood-2024-199263

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

Assessing the Impact of Digital Education on the Clinical Management of Rare Hematologic Malignancies

Tisheeka Graham, Tariqa Ackbarali, Katie Kowalski, Sharon M. Castellino, Lisa Giulino Roth, Matthew J. Ehrhardt, Matthew Matasar

Blood (2024) 144 (Supplement 1): 7794.

https://doi.org/10.1182/blood-2024-211680

Published: 2024

Journal Articles

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Blood (2024) 144 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2024-199675

Published: 2024

Journal Articles

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2023-189652

Published: 2023

Journal Articles

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Keri Toner, Hema Dave, Gloria Pezzella, Qinglin Pei, Terzah M. Horton, Kara M. Kelly, Lisa Giulino Roth, Sharon M. Castellino, Catherine M. Bollard

Blood (2023) 142 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2023-180791

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Christine Mauz-Koerholz, Auke Beishuizen, Luciana Vinti, Antony Ceraulo, Gerard Michel, Michaela Cepelova, Franca Fagioli, Constantino Sabado Alvarez, Stephane Ducassou, Salvatore Buffardi, Maitane Andión Catalan, Brad Hoppe, Frank Keller, Kara M. Kelly, Lisa Giulino Roth, Judith Landman-Parker, Juan Shen, Pallavi Pillai, Stephen Daw

Blood (2023) 142 (Supplement 1): 3063.

https://doi.org/10.1182/blood-2023-187028

Published: 2023

Journal Articles

Classic Hodgkin Lymphomas Display Neuronal-Glial Lineage Transdifferentiation

Blood (2023) 142 (Supplement 1): 715.

https://doi.org/10.1182/blood-2023-189533

Published: 2023

Journal Articles

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Blood (2023) 142 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2023-186719

Published: 2023

Journal Articles

Pembrolizumab in PMBCL: can it go the distance?

Lisa Giulino-Roth

Blood (2023) 142 (2): 121–122.

https://doi.org/10.1182/blood.2023020813

Published: 2023

Journal Articles

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Giorgia Zanetti, Giuseppina Astone, Luca Cappelli, William Chiu, Maria Teresa Cacciapuoti, Clarisse Kayembe, Danilo Fiore, Wayne Tam, Joseph Scandura, Silvana Di Giandomenico, Lorenzo Galluzzi, Lisa Giulino Roth, Giorgio Inghirami

Blood (2021) 138 (Supplement 1): 2406.

https://doi.org/10.1182/blood-2021-151598

Published: 2021

Journal Articles

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J Deyell, Jaime Flerlage, Anna Franklin, Jennifer Krajewski, Kasey J Leger, Lianna Marks, Robin Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul Harker-Murray, Lisa Giulino Roth

Blood (2021) 138 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2021-151808

Published: 2021

Journal Articles

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

Blood (2021) 138 (Supplement 1): 805.

https://doi.org/10.1182/blood-2021-148663

Published: 2021

Journal Articles

HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?

Genevieve M Crane, Dmitry Tychinin, Anton Karelin, Aleksandr Cherdintsev, Olga Kudryashova, Evgeniy Egorov, Sandrine Degryse, Nikita Kotlov, Alexander Bagaev, Joseph Casano, Jonathan Reichel, Lisa Giulino Roth, Mikhail Roshal, Sakellarios Zairis, Raul Rabadan, Olivier Elemento, Giorgio Inghirami, Ethel Cesarman

Blood (2021) 138 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2021-146336

Published: 2021

Journal Articles

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Lisa Giulino-Roth, Qinglin Pei, Allen Buxton, Rizvan Bush, Yue Wu, Suzanne L. Wolden, Louis S. Constine, Kara M. Kelly, Cindy L. Schwartz, Debra L. Friedman

Blood (2021) 137 (11): 1449–1456.

https://doi.org/10.1182/blood.2020007225

Published: 2021

Includes: Supplemental data

Journal Articles

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth

Blood (2020) 135 (21): 1870–1881.

https://doi.org/10.1182/blood.2019004126

Published: 2020

Includes: Supplemental data

Journal Articles

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Destini Gibbs, Herman Van Besien, BA, Stephenson Regan, Ankur Singh, PhD, Matthew Teater, Ethel Cesarman, MD PhD, Ari Melnick, MD, Lisa Giulino Roth, MD

Blood (2019) 134 (Supplement_1): 304.

https://doi.org/10.1182/blood-2019-126790

Published: 2019

Journal Articles

How I treat primary mediastinal B-cell lymphoma

Lisa Giulino-Roth

Blood (2018) 132 (8): 782–790.

https://doi.org/10.1182/blood-2018-04-791566

Published: 2018

NARROW

Combined Epigenetic Therapy to Induce Latency II/III Antigen Expression in Latency I EBV + Lymphoma

Single Cell Transcriptome of Epstein Barr Virus-Associated Burkitt Lymphoma from People Living with Human Immunodeficiency Virus

Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Assessing the Impact of Digital Education on the Clinical Management of Rare Hematologic Malignancies

Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331

Pembrolizumab (pembro) in Children and Young Adults with High-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Updated Results from the Phase 2 Keynote-667 Study

Classic Hodgkin Lymphomas Display Neuronal-Glial Lineage Transdifferentiation

Pembrolizumab (pembro) in Children and Young Adults with Low-Risk Classical Hodgkin Lymphoma (cHL) with Slow Early Response (SER) to Front-Line Chemotherapy (chemo): Early Results from the Phase 2 Keynote-667 Study

Pembrolizumab in PMBCL: can it go the distance?

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Molecular Evolution of Classical Hodgkin Lymphoma Revealed Though Whole Genome Sequencing of Hodgkin and Reed-Sternberg Cells

HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Epigenetic reprogramming sensitizes immunologically silent EBV + lymphomas to virus-directed immunotherapy

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

How I treat primary mediastinal B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only